Literature DB >> 27174093

Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid.

Hui Fang1, Shuai Shao1, Tianyu Cao1, Jie Lei1, Erle Dang1, Jieyu Zhang1, Gang Wang2.   

Abstract

BACKGROUND: Bullous pemphigoid (BP) is the most common blistering autoimmune disease severely affecting older people. The complex interplay between innate and adaptive immunity is critical in the development of BP. Inflammasomes, which lead to cleavage-induced maturation of pro-inflammatory cytokines, have been shown to participate in a variety of autoimmune diseases. However, the role of inflammasomes in BP has not been delineated.
OBJECTIVE: The present work aimed to investigate whether inflammasomes are involved in the pathogenesis and progression of BP.
METHODS: Expressions of inflammasome components at the messenger RNA (mRNA) and protein levels in peripheral blood mononuclear cells (PBMCs) from patients with BP and from healthy controls were investigated by quantitative real-time PCR (qRT-PCR) and western blot, respectively. ELISA was employed to evaluate interleukin (IL)-1β, IL-18, lactate dehydrogenase (LDH), and high-mobility group-1 (HMGB1) levels in the serum and blister fluid of patients with BP. Immunohistochemical staining was used to detect IL-18 expression in the skin lesion of patients with BP.
RESULTS: The mRNA levels of NLRP3 inflammasome components (NLRP3, pro-caspase-1, and pro-IL-18) in PBMCs were significantly up-regulated in BP patients compared with those in healthy controls, and were positively correlated with the autoantibody titers for BP180-NC16A. Western Blot analysis showed that the baseline expressions of NLRP3 inflammasome components were increased in PBMCs of BP patients compared with healthy controls, and we failed to observe the mature IL-1β and IL-18. Further analysis showed that IL-18 was elevated in serum, blister fluid and lesional skin from patients with BP, and the serum IL-18 level was positively correlated with the titers of anti-BP180-NC16A autoantibody in BP patient. Most importantly, we found that mRNA expressions of the NLRP3-caspase-1-IL-18 axis components and the serum IL-18 level in BP patients decreased dramatically after effective treatment, which indicated that the up-regulation of NLRP3 inflammasome was responsible, at least to a great degree, for the enhanced IL-18 level in BP patients.
CONCLUSIONS: This study demonstrates that the expression of the NLRP3-caspase-1-IL-18 axis is highly expressed in the PBMCs of patients with BP, and correlated with disease activity, suggesting its involvement in the pathogenesis and progression of BP.
Copyright © 2016 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Bullous pemphigoid; Interleukin-18; NLRP3 inflammasome

Mesh:

Substances:

Year:  2016        PMID: 27174093     DOI: 10.1016/j.jdermsci.2016.04.009

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  9 in total

1.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 3.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS.

Authors:  Farzan Solimani; Dario Didona; Jing Li; Lei Bao; Payal M Patel; Giulia Gasparini; Khalaf Kridin; Emanuele Cozzani; Michael Hertl; Kyle T Amber
Journal:  Arch Dermatol Res       Date:  2021-06-21       Impact factor: 3.033

Review 5.  Current Clinical Trials in Pemphigus and Pemphigoid.

Authors:  Kentaro Izumi; Katja Bieber; Ralf J Ludwig
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 6.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

7.  Commentary: Proinflammatory role of blister fluid-derived exosomes in bullous pemphigoid.

Authors:  Yangchun Liu; Li Li
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

8.  IL-23/IL-17 Axis Activates IL-1β-Associated Inflammasome in Macrophages and Generates an Auto-Inflammatory Response in a Subgroup of Patients With Bullous Pemphigoid.

Authors:  Sébastien Le Jan; Céline Muller; Julie Plee; Anne Durlach; Philippe Bernard; Frank Antonicelli
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

Review 9.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.